Status:
UNKNOWN
COPD and Inflammatory Mediators
Lead Sponsor:
Faculty of Medicine, Sousse
Conditions:
COPD
Eligibility:
MALE
50-70 years
Phase:
NA
Brief Summary
Chronic obstructive pulmonary disease (COPD) is widely spread all over the world. It is predicted to be the third leading cause of death by 2020.
Detailed Description
COPD is a common, preventable treatable disease that is characterized by an airflow limitation which is not fully reversible.Not only the long-term exposition to noxious particles and gases contribute...
Eligibility Criteria
Inclusion
- COPD diagnosed by pulmonary function testing
- Clinically stable
- Abscence of other obstructive diseases
- Signed written consent
Exclusion
- Neuromuscular diseases -Severe psychiatric, neurologic or musculoskeletal conditions
- cardiovascular diseases.
- Contre-indications to physical therapy
- Acute exacerbations a month before the intervention
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04271124
Start Date
May 1 2020
End Date
July 1 2020
Last Update
February 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Laboratoire de Recherche : Physiologie de l'Exercice et Physiopathologie
Sousse, Tunisia, 4002